Physician profile
Benjamin Hewitt
NPI 1982145181
$4,484.40
in general payments reported to CMS, 2019-2025
24 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $157 · 2023: $487 · 2024: $1,829 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121 · Education: $48.95 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.43 |
| Education | $48.95 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.28 | 2022-2025 | |
| Genzyme Corporation | $629.04 | 2023-2025 | |
| Janssen Biotech, INC. | $507.28 | 2023-2025 | Tremfya, Stelara, Remicade |
| Boston Scientific Corporation | $424.59 | 2022-2025 | General - Therapies, Acquire, Jagtome Rx 39 |
| Phathom Pharmaceuticals, INC. | $220.92 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $215.85 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $171.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.81 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $156.34 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $133.72 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2021 | |
| Medtronic, INC. | $114.51 | 2024-2025 | Interstim |
| Pfizer INC. | $110.84 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $96.55 | 2024-2025 | Vowst, Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $89.48 | 2023-2025 | Entyvio, Gattex |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $78.19 | 2024-2025 | |
| Gilead Sciences, INC. | $76.88 | 2025 | |
| Merck Sharp & Dohme LLC | $39.19 | 2024 | Dificid |
| Conmed Corporation | $32.70 | 2025 | Conmed Biliary |
| Fresenius Kabi USA, LLC | $31.15 | 2024 | Idacio |
| Braintree Laboratories, INC. | $27.28 | 2023 | Suflave, Sutab |
| Qol Medical, LLC | $20.95 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $16.22 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.17 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.